Clinical trials for Adenocarcinoma of the oesophagus and oesophagogastric junction
16 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07432295Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)I-Mab Biopharma US Limited
- RECRUITINGPhase 1NCT07059299A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · PI: Florian Lordick, Prof. Dr.
- RECRUITINGPhase 1NCT07284186First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsPlexium, Inc. · PI: Chief Medical Officer
- RECRUITINGPhase 2NCT06161818Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric JunctionErasmus Medical Center · PI: Bianca Mostert, MD, PhD
- RECRUITINGPhase 2NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaAbbVie · PI: ABBVIE INC.
- RECRUITINGPhase 2NCT05563766A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerVA Office of Research and Development · PI: David H Wang, MD PhD
- RECRUITINGN/ANCT06649474Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1University Hospital, Clermont-Ferrand · PI: Marine JARY, MD
- RECRUITINGPHASE1, PHASE2NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPHASE1, PHASE2NCT06324357Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadBoehringer Ingelheim
- RECRUITINGPhase 1NCT06266299A Study of KK2269 in Adult Participants With Solid TumorsKyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT05480384Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionBrown University · PI: Howard Safran, MD
- RECRUITINGPHASE1, PHASE2NCT06005493Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsAstraZeneca
- ACTIVE NOT RECRUITINGPhase 2NCT04929392Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerCity of Hope Medical Center · PI: Vincent Chung, MD
- RECRUITINGNCT04290806Registry Platform Gastric/Esophageal Cancer (SAPHIR)iOMEDICO AG · PI: Tobias Dechow, Prof.
- ACTIVE NOT RECRUITINGPhase 2NCT03488667Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach AdenocarcinomaUniversity of Kansas Medical Center · PI: Weijing Sun, MD, FACP
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02962063Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerMemorial Sloan Kettering Cancer Center · PI: Geoffrey Ku, MD